venBio Global Strategic Fund IV, L.P. bought ATTO
August 6, 2026 · Form 4 insider transaction
venBio Global Strategic Fund IV, L.P. bought 665,147 shares of Attovia Therapeutics, Inc., a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 4 days after the transaction.
Footnotes
In connection with the completion of the Issuer's initial public offering of its common stock ("Common Stock"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration.; These securities are held directly by venBio Global Strategic Fund IV, L.P. ("Fund IV"). venBio Global Strategic GP IV, LLC ("General Partner IV") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the "rule of three," each disclaims beneficial ownership over the securities held directly by Fund IV.